Загрузка...
Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
BACKGROUND: Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare cancers. In order to provide more insights in drugs for rare neoplastic disorders...
Сохранить в:
| Опубликовано в: : | Orphanet J Rare Dis |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5314481/ https://ncbi.nlm.nih.gov/pubmed/28209180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-017-0578-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|